Elina Koustoumpardi

Senior Consultant
Elina Koustoumpardi Antitrust Competition Charles River Associates

Elina Koustoumpardi joined CRA (formerly Lexecon) in 2002. During her tenure, she has advised clients in mergers, Art. 101 & 102 cases as well as follow-on damages cases arising from anti-competitive conduct both before the EU and national competition authorities in Europe, China and South Africa, in sectors ranging from pharmaceuticals, carton packaging, aviation, mining and telecoms.

In her more recent work she has provided economic advice to a large carton packaging producer being investigated for anti-competitive practices in China, has provided economic advice and supporting analysis in a number of pharmaceutical mergers including Novartis/GSK, Pfizer/Hospira, Teva/Mylan and co-authored a study on the economic impacts of changing exemption provisions during patent and SPC protection of pharmaceuticals in Europe.

Selected engagements

  • 01
    European Commission fines Teva €462.6 million for antitrust abuse
    The Commission found that Teva had abused its dominant position by engaging in two types of conduct. First, it misused the patent system to artificially...
    View engagement
  • 02
    European Commission clears Cooper’s acquisition of Viatris’ European OTC business
    The transaction involved a number of horizontal overlaps in areas including antiseptics and disinfectants, laxatives, warts and corns, joint and muscular pain,...
    View engagement
  • 03
    CRA Competition team advises on Microsoft’s acquisition of Activision Blizzard across jurisdictions worldwide
    On October 13, 2023, the Competition and Markets Authority (CMA) announced that it would clear Microsoft’s acquisition of Activision Blizzard – subject to...
    View engagement

Credentials

Get In Touch